These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20506118)

  • 1. In-hospital and nine-month outcomes among patients with coronary lesions involving a side branch and treated with bare metal stents.
    Novack V; Battaglia L; Popma JJ; Cutlip DE
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):951-7. PubMed ID: 20506118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term risk of clinical events from stenting side branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: an observational meta-analysis.
    Zamani P; Kinlay S
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):202-12. PubMed ID: 20824754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
    Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
    Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial.
    Applegate R; Hermiller J; Williams J; Gordon P; Doostzadeh J; Cao S; Su X; Sudhir K; Lansky A; Simonton C; Stone G
    Catheter Cardiovasc Interv; 2010 Nov; 76(5):644-51. PubMed ID: 20506356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and mid-term clinical outcomes with the CATANIA coronary stent system vs. bare metal stents in patients with coronary artery disease.
    Capodanno D; La Manna A; Di Salvo ME; Sanfilippo A; Corcos T; Tamburino C
    Cardiovasc Revasc Med; 2009; 10(4):216-20. PubMed ID: 19815167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choice of stenting strategy in true coronary artery bifurcation lesions.
    Lin QF; Luo YK; Lin CG; Peng YF; Zhen XC; Chen LL
    Coron Artery Dis; 2010 Sep; 21(6):345-51. PubMed ID: 20613498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized TRYTON bifurcation study.
    Généreux P; Kini A; Lesiak M; Kumsars I; Fontos G; Slagboom T; Ungi I; Metzger DC; Wykrzykowska JJ; Stella PR; Bartorelli AL; Fearon WF; Lefèvre T; Feldman RL; Tarantini G; Bettinger N; Minalu Ayele G; LaSalle L; Francese DP; Onuma Y; Grundeken MJ; Garcia-Garcia HM; Laak LL; Cutlip DE; Kaplan AV; Serruys PW; Leon MB
    Catheter Cardiovasc Interv; 2016 Jun; 87(7):1231-41. PubMed ID: 26397982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
    Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
    JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital-(Research) Registry.
    Shen ZJ; García-García HM; Garg S; Onuma Y; Schenkeveld L; van Domburg RT; Serruys PW;
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):979-86. PubMed ID: 19753636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
    Leon MB; Allocco DJ; Dawkins KD; Baim DS
    JACC Cardiovasc Interv; 2009 Jun; 2(6):504-12. PubMed ID: 19539253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: a retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial.
    Jeger RV; Brunner-La Rocca HP; Hunziker PR; Tsakiris DA; Kaiser CA; Pfisterer ME;
    Clin Ther; 2009 Dec; 31(12):2886-93. PubMed ID: 20110027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
    Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes with cobalt-chromium bare-metal vs. drug-eluting stents: the REgistro regionale AngiopLastiche dell'Emilia-Romagna registry.
    Manari A; Ortolani P; Guastaroba P; Marzaroli P; Menozzi M; Magnavacchi P; Varani E; Vignali L; Campo G; Marzocchi A
    J Cardiovasc Med (Hagerstown); 2011 Feb; 12(2):102-9. PubMed ID: 20814313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
    Lansky AJ; Yaqub M; Hermiller JB; Smith RS; Farhat N; Caputo R; Williams JE; Sanz M; Koo K; Sood P; Sudhir K; Stone GW
    EuroIntervention; 2010 Dec; 6 Suppl J():J44-52. PubMed ID: 21930490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of multivessel stenting on top of percutaneous revascularization for unprotected left main disease in the drug-eluting stent era: insights from the Turin registry.
    Sheiban I; Sillano D; Biondi-Zoccai G; Moretti C; Garrone P; Lombardi P; Sciuto F; Omedè P; Iacovino C; Spina CL; Trevi GP
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):461-8. PubMed ID: 19395977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.